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We sought to systematically review the evidence supporting the role of drug coated 
balloons (DCBs) in the treatment of coronary bifurcation lesions. 
 
Background 
DCBs are emerging as an attractive alternative treatment strategy for treating coronary 
bifurcations due to simplifying the approach and reducing rates of stent related 
complications. We systematically reviewed the evidence for DCB use in coronary 
bifurcations and conducted a focused meta-analysis on late lumen loss in the side branch 
comparing DCB and plain old balloon angioplasty (POBA).  
 
Methods 
This study was conducted in line with the PRISMA statement. All studies (including both 
RCTs and observational studies, excluding case reports) using DCB as part of a bifurcation 
strategy were included in this review. A literature search identified a total of ten studies for 
inclusion. A focused meta-analysis was undertaken for the use of DCB in side-branch 




DCB was found to be superior to POBA for side branch treatment in bifurcations (p=0.01) . 
There are four studies that investigated the use of DCB for main branch treatment in a 
bifurcation, with evidence supporting its safety in main branches of bifurcation lesions, 
while prospective observational studies have demonstrated favourable target lesion 
revascularisation rates. 
Conclusion  
Although there is a lack of robust RCTs comparing DCBs with current generation DES, DCBs 
appear safe in main branch bifurcation lesions with improved side branch late lumen loss 








A coronary bifurcation lesion is defined as a lesion occurring at, or adjacent to, a significant 
division of a major epicardial vessel. [1]  Bifurcation lesions account for 1 in 5 of all cases 
requiring percutaneous coronary intervention (PCI) [1] and are associated with worse 
outcomes than non-bifurcation PCI. [2] Treatment strategies for these lesions are complex 
and there remains a lack of consensus on the best approach. We therefore systematically 
reviewed the evidence supporting the use of drug coated balloons (DCBs) as an alternative 
to complex stenting.  
 
The current European Society of Cardiology (ESC) guidelines [3] recommend main branch-
only stenting with provisional side-branch stenting as the preferred strategy due to reduced 
procedure time, contrast load, radiation dose and a lack of evidence supporting superiority 
of a two-stent strategy. [4] [5] The European Bifurcation Club also supports the use of a 
main branch-only stenting in the majority of cases with provisional side branch stenting only 
if required due to severe side-branch recoil or flow limitations after stenting the main 
branch. [1] 
 
Given the complexity of coronary bifurcation anatomy with significant size mismatch 
between proximal and distal main branch which may drive rates of instent restenosis [6] 
and the potential impact of main branch stenting affecting side-branch coronary flow 
dynamics [7], the concept of leaving no permanent implant behind is appealing.  
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DCBs are a standard semi-compliant angioplasty balloon, coated in a cytotoxic 
chemotherapeutic agent, most commonly paclitaxel. Their use in angioplasty is currently 
recommended by ESC guidelines for in-stent restenosis only. [3] There is increasing evidence 
supporting their use in de novo small and large vessels. [8–10] Their use in bifurcation 
lesions is appealing as it would provide a more straight-forward treatment strategy, 
theoretically reduce rates of lesion thrombosis [1] which drive adverse outcomes, side-
branch re-stenosis which occur in up to 10% [11] and prevent loss of side branches due to 
the lack of stent strut jailing. With the guidelines and evidence supporting the KISSS (keep it 
swift, simple and safe) principle [12], DCBs appear an attractive alternative. The European 
Bifurcation Club’s latest meeting has highlighted DCBs as an area of interest for bifurcation 
PCI [13] with a recent international DCB consensus group highlighting the role of DCBs in 
bifurcation lesions. [14] 
 
As such, we sought to systematically review the existing literature for the use of DCBs in 
coronary bifurcation lesions.  
 
Materials and Methods 
The study was conducted according to the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses statement (PRISMA). A systematic search was conducted on 
PubMed (1946- 10th August 2020) and Scopus by two independent researchers, using the 
MeSH search terms “drug coated balloon”, “drug eluting balloon”, “PCI” and “bifurcations” 
in August 2020 and a further review of the references of the relevant papers were included. 
All study designs that used a drug coated balloon in treatment of a coronary bifurcation 
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lesion (either main branch, side branch or combined strategy) were included.  This included 
randomised controlled trials, prospective observational studies and both prospective and 
retrospective registries. Case reports were excluded. Only full studies were included. All 
clinical presentations (stable angina, acute coronary syndromes including STEMI) were 
included.  The exclusion criteria were any study not assessing the use of drug coated balloon 
for treating a coronary bifurcation lesion. The primary outcome measures included MACE 
and angiographic follow-up measures encompassing late lumen loss and binary restenosis 
rate using quantitative coronary angiography. The review was not registered with 
PROSPERO.  
 
Two independent researchers (NC and SP) extracted data from downloaded PDFs of studies 
into a pre-tabulated excel spreadsheet. This included data on 1) publication details (notably, 
study reference, main author, year of publication), 2) study design and methodology, 3) 
participants including baseline characteristics and sample size and 4) outcomes. Baseline 
patient characteristics that were extracted included: mean age, sex, risk factors including 
smoking, hypertension, diabetes, dyslipidaemia, MI, previous PCI and clinical presentation. 
The lesion characteristics extracted included vessel treated and Medina Classification. 
Clinical outcomes recorded included major adverse cardiovascular outcomes (MACE),  
target lesion revascularisation and angiographic outcomes including late lumen loss, 
angiographic restenosis and mean lumen area. Due to heterogeneity of study design, a 
systematic review was undertaken, but a subgroup meta-analysis has also been conducted 
for DCB use in the side branch (using a random effects model) but the primary aim was to 
systematically review the literature on the use of DCBs in coronary bifurcations.  
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The Cochrane Risk of Bias Assessment tool (RoB 2) was used to identify quality of included 
papers for the randomised controlled trials, covering five domains: 1. The randomisation 
process, 2. Deviations from the intended interventions, 3. Missing outcome data 4. 
Measurement of the outcome and 5. Selection of the reported result. This was conducted 
by two independent investigators. Statistical analysis was conducted using Review Manager 
5.3 for MacOS with summary statistics from each study expressed as mean lumen loss, 
before combining these statistics from each study, using a random effects model with 
difference between the two outcomes expressed as mean difference with 95% confidence 
intervals, and I2 to assess for heterogeneity. Statistical significance was set at p<0.05. 
 
Results 
Of 37 papers identified in the initial search, 12 papers were included in analysis. Two 
registry trials were for all-comer DCB use, and the investigators were contacted for 
outcomes for subgroup analysis for bifurcation lesions although such data was unavailable. 
Figure 1 represents the search strategy, in accordance with PRISMA guidelines.  
 
Patient Characteristics 
As shown in table 1, the majority of patients were male (75.4 %) with a mean age of 64.9 
(10.7). The most frequently occurring risk factors were hypertension (70.5%) and 
dyslipidaemia (63.8%). The majority of studies featured predominantly patients with stable 








Year Study design Intervention Sample 
size 
Age Male Smoking 
PEPCAD-V [15]  2011 Prospective 
observational 
study 








DEBIUT [16] 2012 RCT BMS MB/DCB SB 
BMS MB/ POBA SB 
DES MB/POBA SB 
117 63.67.8 85 (72.6%) 69 (58.9%) 
Herrador et al. [17]  2013 RCT DCB v POBA to SB 100 62.510.6 83 (83%) 52 (52%) 
BABILON [18] 2014 RCT MB BMS and SB 
DCB v. MB DES and 
SB POBA 
 
108 64.811.2 70 (64.8%) 54 (50%) 
Schulz et al [19] 2014 Prospective 
observational 
study 
DCB only 38 70.711.9 
 
23 (60.5%) ND 
BIOLUX-I [20] 2015 Prospective 
observational 
study 
DES to MB and DCB 
to SB 












Bruch et al [22] 2016 Prospective 
registry 
DCB only (bailout 







Vaquerizo et al [23] 2016 Prospective 
registry 






Her et al [24] 2016 Prospective 
observational 
study 
DCB to MB with 

























PEPCAD-V 4 (14.3%) 24 (85.7%) 17 (60.7%) 10 (35.7%) 5 (17.9%) ND 28 (100%) 0 (0%) 
 
DEBIUT 13 (11.1%) 67 (57.5%) 65 (55.6%) ND 25 (21.4%) 38 (32.5%) ND ND 
 
Herrador et al 33 (33%) 62 (62%) 56 (56%) ND 12 (12%) 9 (9%) 24 (24%) 76 (76%) 
 
BABILON 34 (31.5%) 67 (62%) 69 (63.9%) ND 27 (25%) 19 (17.6%) ND 47 (43.5%) 
 
Schulz et al 17 (44.7%) 35 (92.1%) 20 (52.6%) ND ND ND 21 (53.8%) 18 (46.2%) 
 









PEPCAD-BIF 23 (35.9%) 
 
ND ND ND 12 (18.8%) 
 
ND 41 (64.1%) 15 (23.4%) 




ND ND ND 69 (54.3%) 21 (16.5%) 
Vaquerizo et al 20 (40.8%) 26 (53.1%) 30 (61.2%) ND 8 (16.3%) 16 (32.7%) ND 30 (65.3%) 
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Her et al 4 (25%) 7 (43.8%) 8 (50.0%) 
 
2 (12.5%) ND ND 11 (68.6%) 5 (31.2%) 
 
Where age is expressed as meanstandard deviation, and all other numbers are presented as number (%). MB=main branch, BMS=bare 
metal stent, DCB= drug coated balloon, SB= side-branch, DES= drug eluting stent, POBA= plain old balloon angioplasty, RCT= randomised 





Angiographic/ lesion characteristics  
Of a total of 688 lesions included, the majority of lesions treated were left anterior 
descending (LAD)/ diagonal (DG) bifurcations (63.4%), with 25.3% accounting for circumflex 
(Cx)/ obtuse marginal (OM) bifurcations and 8% right coronary artery (RCA)/ posterior 
descending artery (PDA) bifurcations. Some seven of the included studies excluded left main 
stem (LMS) disease so this only accounted for 3.3% of lesions treated. The Medina 
Classification is summarised in Table 2.  
 





Bifurcation treated Medina Classification 
 LMCA LAD Cx RCA 1,1,1 1,1,0 1,0,1 0,1,1 1,0,0 0,1,0 0,0,1 










2 (7.1%) 3 
(10.7%) 
1 (3.6%) 




3 (2.6%) ND ND ND ND ND ND ND 
Herrador et 
al.  






ND ND ND ND ND ND ND 








ND ND ND ND ND ND 










1 (2.6%) 7 
(17.9%) 




BIOLUX-I N/A 29 
(82.8%) 
























N/A N/A N/A 2 (6.3%) 
3 (9.4%) 


























4 (8.2%) N/A N/A N/A N/A N/A N/A 49 
(100%) 
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Her et al. N/A 21 
(80.8%) 
















DCB for Side-Branch only 
PEPCAD-V (2011)[15] paved the way for the use of DCB in side-branch of bifurcation lesions 
as a first-in-man observational study with the use of bare metal stent (BMS) in the main 
branch, reporting a mean late lumen loss at 9 month angiography of 0.210.48.  
DEBIUT (2012) [16], Herrador et al. (2013) [17] and BABILON (2014) [18] all compared the 
performance of DCB to the side-branch of a bifurcation lesion with either plain old balloon 
angioplasty (POBA) or DES, all using late lumen loss (LLL) at angiographic follow-up as 
primary outcomes.  
 
We conducted a subgroup meta-analysis for side branch late lumen loss in these three 
studies (n=281). This showed a statistically significant difference favouring DCB over POBA 
(p=0.01). A random effects model was used. Of interest, Herrador et al. was the only trial 
individually to show statistically significant benefit of DCB over POBA and this was the only 
study design that used a DES in the main branch rather than BMS. 
 





Of the non-randomised, prospective single-arm trials, BIOLUX-1 (2015) [20] and Vaquerizo 
et al. (2016) [23] both reported favourable late lumen loss at follow up angiography for DCB 
to side-branch. For BIOLUX-1 (n=28), mean LLL for side-branch was 0.10.43 [20] and 
Vaquerizo (n=31), LLL for SB was 0.320.73, although notably, bailout stenting in this cohort 
was high at 14%. [23] 
 
DCB as a main branch (MB) strategy  
Schulz et al. (2014) performed a single arm, prospective observational study looking at a 
DCB only strategy for bifurcations (n=39). Of these, 33.3% were LMS bifurcation lesions and 
46% were true bifurcation lesions (1,1,1; 1,1,0 or 0,1,1). With a primary outcome of 
angiographic restenosis at follow-up angiography, 3 (10% as n=30) had angiographic 
evidence of restenosis- all of these were LMS disease. [19]  
PEPCAD-BIF (2016) randomised patients (n=64) to either DCB or POBA only approach for 
bifurcation lesions that did not incorporate proximal main branch disease (i.e. Medina 0,1,0, 
0,0,1 or 0,1,1). It incorporated largely small vessels (mean vessel diameter 2.4mm). This 
showed a statistically significant improvement in late lumen loss favouring the DCB arm 
(0.13 v 0.51, p=0.013). [21] As the first DCB only randomised trial, this showed promising 
results for the use of DCB only bifurcation.   
 
Bruch et al. (2016) conducted a prospective registry of a DCB only strategy for coronary 
bifurcation lesions of any medina classification. Of these, 97 (74.6%) were a true bifurcation 
lesion and the mean vessel diameter of the main branch was 2.98. The primary outcome 
was target lesion revascularisation (TLR) at 9 months with a TLR rate of 3 (4.5%) with a 
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cumulative MACE of 4 (6.1%). These outcomes show the promise of a DCB only strategy 
although there was a high bailout stenting rate of 45%.   
 
Her et al. (2016)  performed a single centre, prospective observational study (n=16) using a 
DCB only approach for the main branch with a primary outcome of OCT lumen area of both 
main branch and side branch at angiographic follow-up. There was a significant increase in 
side-branch mean lumen area at 9 months (0.92-1.42, p=0.013) with similar increase in main 
branch mean lumen area (4.77-5.69, p=0.008). [24] 
 
Table 3 summarises the results from all studies not included in the focused meta-analysis.  
 
Where LLL= late lumen loss, MV= main vessel, SB= side branch, RCT= randomised 
controlled trial, TLR= target lesion revascularisation, MACE= major adverse cardiovascular 
outcomes, OCT= optical coherence tomography 
First author/ trial/ 
reference 
Study design Primary outcome Result 
PEPCAD-V [15] Prospective 
observational study 
LLL at 9 months MV LLL: 0.38 ± 0.46 
mm 
SB LLL: 0.21 ± 0.48mm 
 
 
Schulz et al [25] Prospective 
observational study 





BIOLUX-I [26] Prospective 
observational study 
Side-branch LLL at 9 
months 
SB LLL: 0.1 ± 0.43 mm 
 
 
PEPCAD-BIF [21] RCT LLL at 9 months LLL: 0.13 v 0.51 mm 
(p=0.001) 
 
Bruch et al [27] Prospective 
observational study 
TLR at 9 months TLR for DCB only: 4.5% 
 
Vaquerizo et al [23] Prospective registry MACE at 12 months MACE: 16.3% 
 
Her et al [24] Prospective 
observational study 
Side-branch ostial 
lumen area at 9 
months (OCT) 








The cardiology community still remains uncertain as to the best strategy to treat coronary 
bifurcations. The subgroup meta-analysis shows that DCB is superior to POBA for side 
branch only treatment in bifurcation disease with regards to late lumen loss at follow-up 
angiography. Individually, only one study showed statistical significance which may be due 
to the use of stents across the ostium of the main branch in all cases and particularly, the 
use of BMS as opposed to DES in the DCB arms which is likely to drive any increase in MACE 
rates. As there is now evidence supporting the use of DCBs in small vessel coronary disease 
[9], it follows that DCBs would be an effective treatment option for side-branch lesions in 
coronary bifurcations, and this has been confirmed in this sub-group meta-analysis. 
 
The evidence supporting a DCB only bifurcation strategy is of interest. The results of 
PEPCAD-BIF [21] showed DCB is superior to POBA for main branch bifurcation lesions, 
although this only looked at DCB use in either the distal main branch or side-branch, but it 
did include both small and large vessels.  Bruch et al [27] also add strength to the argument 
for a DCB only strategy, with promising MACE rates of 6.1%, whereas a comparable lesion 
complexity DES cohort reports a MACE of 20.8% for a simple stent strategy. [12] The results 
of Her et al [24] are of particular interest. Although this is a small patient group, and a single 
arm observational study, it confirms that when a DCB is used to treat the main branch, there 
is a significant increase in the ostial side-branch area at follow-up OCT. This is of benefit in 
reducing the high rates of ISR currently associated with side-branches in bifurcation lesions. 
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[28] With regards to cost-effectiveness, although the shelf-cost of a DCB is higher than a 
DES, the reduced procedural complexity requiring less equipment, particularly with a two 
stent strategy including kissing balloon inflation makes DCB a cost-effective alternative, 
although no formal cost-effectiveness analysis has been undertaken. In addition, in our 
practice we find that with DCB less intravascular imaging is required making it overall 
cheaper for this type of patients.  
 
Based on this review, and our experience with the use of DCBs in bifurcation lesions, we 
would suggest the following strategies to treating a bifurcation lesion with a DCB strategy. If 
the operator’s preference is a DES approach to the main vessel, the use of a DCB for the side 
branch can be used upfront (prior to stenting) if there is significant disease of the side 
branch. The benefit of this over POBA has been confirmed by our sub-group meta-analysis. 
If the side branch is not significantly diseased and the treatment strategy is to treat the 
main vessel only, a DCB can be used to the side branch after stenting if the flow becomes 
compromised as a result of stenting.  
If the operator’s preference is a DCB only strategy, either due to anatomical or patient 
factors, a provisional main vessel approach with a DCB is a good initial option. On the 
registry evidence presented above, a DCB only strategy appears safe in the main vessel. 
From Her et al’s OCT study [24], if there is pinching of the ostium of the side branch after 
DCB to the main vessel, there is no necessity to pursue this as the side branch ostium lumen 
will increase due to positive remodelling. If there is an indication to treat the side branch 
too (e.g. long segment of side branch disease, large vessel, significant territory supplied) [5], 
then a sequential DCB to side branch followed by DCB to main vessel would be a reasonable 
approach.  Based on current DCB consensus guidelines [14], there is usually no need for 
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kissing balloon inflation. The only time when this could be indicated is if there is loss of flow 






Bifurcation studies are difficult to interpret given the lesion variability which will influence 
outcomes and is neither easily describable or accountable for. These factors include the 
bifurcation angle, the significance of the side-branch, the extent of main branch disease and 
the main branch/ side branch size mismatch, none of which is encompassed in Medina 
classification. Despite a wealth of RCTs for DES strategies in bifurcations, uncertainties still 
remain in the best stenting strategy. In comparison, there are a small number of studies 
looking at DCBs in bifurcation lesions. The use of BMS in conjunction with DCB in some of 
the earlier RCTs also will influence interpretation of results. As BMS are associated with 
significantly higher rates of TLR, stent thrombosis (ST) and MI when compared with DES 
[29], in order to understand the performance of DCBs in bifurcations, it needs to be 
compared with current generation DES.   
 
Conclusion 
In summary, it appears that DCBs could be  a potential alternative treatment strategy for 
bifurcations (both main branch and side-branch) with demonstrated safety.  However, there 
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remains a paucity of large registry data confirming their efficacy or RCTs comparing their use 
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Figure legends:  
 
Figure 1 represents the search strategy, in accordance with PRISMA guidelines.  
Figure 2: Forest plot for late lumen loss in DCB v POBA for side branch treatment 
 
